Back

Actinogen Medical completes final XanaMIA trial visit, with results due in November

Verifying
  • Actinogen Medical completed the final patient visit in its XanaMIA trial.
  • Top-line results from the Phase 2b/3 study are expected in November.
  • XanaMIA uses the p-tau181 blood biomarker to select Alzheimer’s patients.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Actinogen Medical completes final XanaMIA trial visit, with results due in November - CoinPost Terminal